← Eichor
Study identifier: NCT04161664 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy

Condition: Metastatic Squamous Cell Carcinoma of the Vulva  ·  Sponsor: The Netherlands Cancer Institute

PhasePhase 2
Planned participants12
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes invalidating and chronic postoperative morbidity, especially in patients with high stage disease. Theoretically, downstaging with neo adjuvant chemotherapy could shrink the tumour, making surgical treatment less extensive thereby diminishing the chance for morbidity.

This description comes directly from the study's public registry record.

Talk to the study team

Frederic Amant, MD, PhD  ·  0031205129111  ·  f.amant@nki.nl

Always discuss trial participation with your own doctor first.

Locations (1)

NKI-AVLAmsterdam, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04161664